Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
about
Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.
P2860
Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Cancer-specific mortality, cur ...... in the immunochemotherapy era.
@en
type
label
Cancer-specific mortality, cur ...... in the immunochemotherapy era.
@en
prefLabel
Cancer-specific mortality, cur ...... in the immunochemotherapy era.
@en
P2093
P2860
P356
P1433
P1476
Cancer-specific mortality, cur ...... in the immunochemotherapy era.
@en
P2093
Angela B Mariotto
Eric A Engels
Gita Suneja
Kim Robien
Nadia Howlader
Naji Younes
P2860
P304
P356
10.1002/CNCR.30739
P407
P577
2017-05-02T00:00:00Z